Last reviewed · How we verify

Diabeton 60 MR

Servier Affaires Médicales · Phase 2 active Small molecule

Diabeton 60 MR is a Sulfonylurea Small molecule drug developed by Servier Affaires Médicales. It is currently in Phase 2 development for Type 2 diabetes mellitus.

Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation.

Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation. Used for Type 2 diabetes mellitus.

At a glance

Generic nameDiabeton 60 MR
SponsorServier Affaires Médicales
Drug classSulfonylurea
TargetPancreatic beta-cell ATP-sensitive potassium channels
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 2

Mechanism of action

Diabeton 60 MR contains gliclazide, which is a sulfonylurea that primarily works by stimulating insulin secretion from pancreatic beta-cells. The sustained-release formulation ensures a steady release of the drug over time, providing consistent blood glucose control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Diabeton 60 MR

What is Diabeton 60 MR?

Diabeton 60 MR is a Sulfonylurea drug developed by Servier Affaires Médicales, indicated for Type 2 diabetes mellitus.

How does Diabeton 60 MR work?

Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation.

What is Diabeton 60 MR used for?

Diabeton 60 MR is indicated for Type 2 diabetes mellitus.

Who makes Diabeton 60 MR?

Diabeton 60 MR is developed by Servier Affaires Médicales (see full Servier Affaires Médicales pipeline at /company/servier-affaires-m-dicales).

What drug class is Diabeton 60 MR in?

Diabeton 60 MR belongs to the Sulfonylurea class. See all Sulfonylurea drugs at /class/sulfonylurea.

What development phase is Diabeton 60 MR in?

Diabeton 60 MR is in Phase 2.

What are the side effects of Diabeton 60 MR?

Common side effects of Diabeton 60 MR include Hypoglycemia, Weight gain.

What does Diabeton 60 MR target?

Diabeton 60 MR targets Pancreatic beta-cell ATP-sensitive potassium channels and is a Sulfonylurea.

Related